Roundtable: Navigating Phase 2 Trials: Ensuring Safety & Efficacy in Gene Therapy for Ophthalmic Disorders
Time: 11:00 am
day: Day Two 12th
Details:
- Exploring the intricate balance between safety and efficacy assessments in phase 2 trials for gene therapy interventions targeting ophthalmic disorders
- Addressing the unique hurdles faced in validating safety parameters and defining efficacy endpoints, particularly in slowly progressive diseases characteristic of ophthalmic disorders
- Strategies for seamless transition from phase 2 to phase 3 trials, emphasizing the critical importance of robust data interpretation, regulatory compliance, and maintaining momentum towards commercialization